Skip to main content

Table 2 AMH and pituitary-gonadal hormones (median ± SD) observed during the menstrual cycle; see also protocol section. Median and 25th and 75th percentile values are reported in brackets

From: Cross-sectional and prospective study on anti-Müllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer

 Group 1
n = 59
Group 2
n = 30
Group 3
n = 141
Significance P
AMH (pmol/l)9.79 ± 11.46 (7.14;1.57–12.29)8.71 ± 10.54 (3.75;1.48–16.13)21.28 ± 23.82 (13.50; 5.14–29.32)< 0.0001; a
FSH (IU/l)12.6 ± 12.4 (8.6; 6.2–13.8)15.3 ± 15.4 (11.0; 6.6–17.9)10.1 ± 12.0 (6.8; 4.9–10.2)0.005; b
Estradiol (pmol/l)210.8 ± 87.6 (176.2; 147–247)162.8 ± 65.9 (168.9; 109–209)204.1 ± 171.3 (157.9;105–209)0.10
Progesterone (nmol/l)22.2 ± 18.1 (22.3; 4.8–33.5)25.2 ± 16.6 (23.4; 14.9–36.4)23.0 ± 24.2 (19.5; 3.7–30.2)0.64
PRL (μg/l)12.3 ± 8.5 (9.6; 6.3–16.0)13.8 ± 6.6 (13.7; 7.6–17.7)14.8 ± 8.4 (13.3; 8.5–18.6)0.06
  1. (When ANOVA was significant, differences among groups were evaluated by means of Dunn’s test. a) AMH: group 3 vs group 1, P = 0.0002 and group 3 vs group 2, P = 0.001; b) FSH: group 3 vs group 1, P = 0.01; group 3 vs group 2, P = 0.06)